EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeted genotyping for recurring variants in cancer susceptibility genes in non‐Ashkenazi Jewish patients with breast cancer diagnosed ≥50 years

Rinat Bernstein-Molho iD, Narmeen Abu Shhada, Yael Laitman, Iris Netzer, Shelley Shoval, Eitan Friedman

Cancer · 2024

DOI: 10.1002/cncr.35329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Rinat Bernstein-Molho und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Suzanne Levy-Gertner Oncogenetics Unit, Sheba Tel Hashomer Medical Center, Ramat-Gan, Israel. Hauptthemen laut MEDLINE: Genetic Predisposition to Disease, Checkpoint Kinase 2, Breast Neoplasms, Jews. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Several recurring pathogenic variants (PVs) in BRCA1/BRCA2 and additional cancer susceptibility genes are described in the ethnically diverse Israeli population. Since 2019, testing for these recurring PVs is reimbursed unselectively for all patients with breast cancer (BC) in Israel. The aim was to evaluate the yield of genotyping for these PVs in non‐Ashkenazi Jewish (AJ) patients with BC diagnosed ≥age 50 years.

Methods

Clinical and genotyping data of all patients with BC undergoing oncogenetic counseling at the Oncology Institute at Sheba Medical Center from June 2017 to December 2023 were reviewed.

Results

Of 2706 patients with BC (mean age at diagnosis, 54 years; range, 20–92 years) counseled, 515 patients of non‐AJ (all four grandparents) descent, diagnosed ≥age 50 years of age were genotyped, 55 with triple‐negative BC (TNBC) and 460 with non‐TNBC. One of the recurring PVs in BRCA1/BRCA2 were detected in 12.7% (7/55) of TNBC patients and 0.65% (3/460) of non‐TNBC. One patient with non‐TNBC had PMS2 PV. Low‐penetrance variants were found in 2.5% of genotyped TNBC and in 3.7% of patients with non‐TNBC, including CHEK2 c.499G>A ( n = 3), APC c.3920T > A ( n = 4), and heterozygous MUTYH c.1187G>A ( n = 5). Following first‐pass genotyping, 146 patients performed multigene panel testing, none carried a BRCA1/BRCA2 PV, and only 5/127 non‐TNBC (3.9%) harbored PVs in CHEK2 ( n = 2, c.846+1G>C and c.592+3A>T), ATM c.103C>T ( n = 2), and NBN c.966C>G ( n = 1).

Conclusions

The observed low rates of PV detection in non‐AJ non‐TNBC cases ≥age 50 years at diagnosis, mostly for clinically insignificant variants, questions the justification of unselected genotyping in this subset of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic Predisposition to DiseaseCheckpoint Kinase 2Breast NeoplasmsJewsBRCA2 ProteinHumansMiddle AgedFemaleAgedAdultAged, 80 and overBRCA1 ProteinIsraelGenotypeYoung AdultAtaxia Telangiectasia Mutated ProteinsMismatch Repair Endonuclease PMS2Adenomatous Polyposis Coli ProteinDNA GlycosylasesTriple Negative Breast NeoplasmsGenetic Testing

Stichwörter der Autor:innen

BRCA1 BRCA2breast cancercancer susceptibility genesnon‐Ashkenazi Jewishrecurring pathogenic variants

Substanzen

Checkpoint Kinase 2CHEK2 protein, humanBRCA2 ProteinBRCA1 ProteinBRCA2 protein, humanBRCA1 protein, humanAtaxia Telangiectasia Mutated ProteinsATM protein, humanMismatch Repair Endonuclease PMS2PMS2 protein, human

Autor:innen und Institutionen

  • The Suzanne Levy-Gertner Oncogenetics Unit, Sheba Tel Hashomer Medical Center, Ramat-Gan, Israel.
  • Faculty of Medical and Health Sciences, School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Breast cancer Institute, The Jusidman Cancer Center, Sheba Tel Hashomer Medical Center, Ramat-Gan, Israel.
  • The Meirav high-risk clinic - Sheba Tel Hashomer Medical Center, Ramat-Gan, Israel.

ORCID-Profile: Rinat Bernstein-Molho

Zitieren

APA

Bernstein-Molho, R., Shhada, N. A., Laitman, Y., Netzer, I., Shoval, S., & Friedman, E. (2024). Targeted genotyping for recurring variants in cancer susceptibility genes in non‐Ashkenazi Jewish patients with breast cancer diagnosed ≥50 years. Cancer. https://doi.org/10.1002/cncr.35329

Vancouver

Bernstein-Molho R, Shhada NA, Laitman Y, Netzer I, Shoval S, Friedman E. Targeted genotyping for recurring variants in cancer susceptibility genes in non‐Ashkenazi Jewish patients with breast cancer diagnosed ≥50 years. Cancer. 2024. doi:10.1002/cncr.35329

BibTeX
@article{BernsteinMolho2024,
  author = {Bernstein-Molho, Rinat and Shhada, Narmeen Abu and Laitman, Yael and Netzer, Iris and Shoval, Shelley and Friedman, Eitan},
  title = {Targeted genotyping for recurring variants in cancer susceptibility genes in non‐Ashkenazi Jewish patients with breast cancer diagnosed ≥50 years},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35329}
}
Kostenlos starten →